Catapol: a promising natural neuroprotective agent for neurologic disorders
Neurologic disorders are the leading cause of illness and disability as a result of increased life expectancy and global population aging, highlighting the urgent need and great challenge for discovering neuroprotective agents with better efficacy and minimal side-effects. Catalpol, an iridoid glyco...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-04-01
|
| Series: | Acta Materia Medica |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850121859127836672 |
|---|---|
| author | Wenting Li Xidan Zhou |
| author_facet | Wenting Li Xidan Zhou |
| author_sort | Wenting Li |
| collection | DOAJ |
| description | Neurologic disorders are the leading cause of illness and disability as a result of increased life expectancy and global population aging, highlighting the urgent need and great challenge for discovering neuroprotective agents with better efficacy and minimal side-effects. Catalpol, an iridoid glycoside derived from Rehmanniae Radix, has therapeutic potential in neurologic diseases due to its diverse biological activities. This review summarizes the research advances and therapeutic potential of catalpol for a wide range of neurologic disorders, including depression, cognitive impairment, stroke, Parkinson’s disease, and multiple sclerosis. A comprehensive discussion of experimental models used, dosages, duration of treatment, and mechanisms involved is provided. The common mechanisms underlying the neuroprotective effects of catalpol on these neurologic disorders are closely related to antioxidant, anti-neuroinflammatory, and anti-apoptotic properties, as well as the capacity to promote neuroplasticity and neurogenesis. Despite the promising results from experimental studies, there are still challenges to be addressed, such as identifying direct binding targets, assessing toxicologic effects, and understanding pharmacokinetics. Furthermore, well-designed and controlled clinical trials should be conducted to validate the efficacy and safety for treating various neurologic conditions. This review provides compelling evidence supporting catalpol as a promising natural neuroprotective agent. |
| format | Article |
| id | doaj-art-ea51172e5fc545d08e9f56730e8d5055 |
| institution | OA Journals |
| issn | 2737-7946 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Acta Materia Medica |
| spelling | doaj-art-ea51172e5fc545d08e9f56730e8d50552025-08-20T02:34:59ZengCompuscript LtdActa Materia Medica2737-79462025-04-014341343610.15212/AMM-2024-0097Catapol: a promising natural neuroprotective agent for neurologic disordersWenting LiXidan ZhouNeurologic disorders are the leading cause of illness and disability as a result of increased life expectancy and global population aging, highlighting the urgent need and great challenge for discovering neuroprotective agents with better efficacy and minimal side-effects. Catalpol, an iridoid glycoside derived from Rehmanniae Radix, has therapeutic potential in neurologic diseases due to its diverse biological activities. This review summarizes the research advances and therapeutic potential of catalpol for a wide range of neurologic disorders, including depression, cognitive impairment, stroke, Parkinson’s disease, and multiple sclerosis. A comprehensive discussion of experimental models used, dosages, duration of treatment, and mechanisms involved is provided. The common mechanisms underlying the neuroprotective effects of catalpol on these neurologic disorders are closely related to antioxidant, anti-neuroinflammatory, and anti-apoptotic properties, as well as the capacity to promote neuroplasticity and neurogenesis. Despite the promising results from experimental studies, there are still challenges to be addressed, such as identifying direct binding targets, assessing toxicologic effects, and understanding pharmacokinetics. Furthermore, well-designed and controlled clinical trials should be conducted to validate the efficacy and safety for treating various neurologic conditions. This review provides compelling evidence supporting catalpol as a promising natural neuroprotective agent.https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0097 |
| spellingShingle | Wenting Li Xidan Zhou Catapol: a promising natural neuroprotective agent for neurologic disorders Acta Materia Medica |
| title | Catapol: a promising natural neuroprotective agent for neurologic disorders |
| title_full | Catapol: a promising natural neuroprotective agent for neurologic disorders |
| title_fullStr | Catapol: a promising natural neuroprotective agent for neurologic disorders |
| title_full_unstemmed | Catapol: a promising natural neuroprotective agent for neurologic disorders |
| title_short | Catapol: a promising natural neuroprotective agent for neurologic disorders |
| title_sort | catapol a promising natural neuroprotective agent for neurologic disorders |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0097 |
| work_keys_str_mv | AT wentingli catapolapromisingnaturalneuroprotectiveagentforneurologicdisorders AT xidanzhou catapolapromisingnaturalneuroprotectiveagentforneurologicdisorders |